Latest Product Development News

WiseTech Global has appointed Zubin Appoo as its permanent CEO, succeeding interim leader Andrew Cartledge who will retire later this year. Appoo’s deep company roots and broad tech leadership experience position him to steer WiseTech’s next chapter.

IMDEX has acquired an 80.5% stake in Norway’s Earth Science Analytics for A$26 million, integrating its AI-driven EarthNET platform to boost digital orebody knowledge across mining and energy sectors.

Openn Negotiation Ltd has successfully exited voluntary administration following creditor approval of a recapitalisation plan, supported by an interest-free loan from its major shareholder. Despite no substantive business activity this quarter, the company now has over two quarters of funding runway.

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Oneview Healthcare reported a €4 million cash outflow in Q2 2025, driven by restructuring and lower R&D credits, while securing new US hospital contracts and expanding AI-powered care solutions.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

icetana Limited reports its strongest quarterly annual recurring revenue growth in over four years, boosted by a landmark $3.6 million strategic partnership with SoftBank Robotics Group and expanding global deployments.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.